Press Release 07.08.26
Steven Green advises emerging growth companies in the life sciences and technology industries across the full spectrum of business and legal issues throughout their corporate life cycles.
He serves as a trusted advisor and guides his clients through company formation, early-stage financings, employment and executive compensation matters, capital raisings, joint ventures, mergers and acquisitions, and initial public offerings. Steven also represents venture capital firms and strategic investors in structuring and executing investments in cutting-edge companies across the innovation economy.
View More
Steven’s transactional work spans a wide range of industries and deal structures, with a focus on high-growth sectors, such as biotechnology, pharmaceuticals, medical devices, diagnostics, digital health, software and enterprise technologies. His practical, business-oriented approach enables clients to navigate evolving legal and regulatory frameworks while advancing their strategic objectives.
Prior to joining Pillsbury, Steven was a partner at the Silicon Valley office of an international law firm.
Representative Experience
Prior to and since joining Pillsbury, Steven’s notable representations include:
- Represented ACELYRIN in its $300 million Series C financing.
- Represented Sword Health in its $163 million Series D financing and $85 million Series C financing.
- Represented Wellth in its $36 million Series C financing and $20 million Series B financing.
View More
- Representative VC Financings Experience
- Represented Medipost in its CAD $90 million joint venture agreement with OmniaBio.
- Represented Vesalius Therapeutics in its strategic alliance agreement with GSK, in which Vesalius will receive $80 million upfront.
- Represented TJM Labs in its $75 million Series B financing.
- Represented Nuvig Therapeutics in its $47 million Series A financing.
- Represented Myrobalan Therapeutics in its $33 million Series A financing.
- Represented Questa Capital in its investment in Vynca’s $30 million funding round.
- Represented TJM Labs in its $10 million Series A financing.
- Represented InpharmD in its $6 million Series Seed financing.
- Representative Mergers & Acquisitions Experience
- Represented TJM Labs in its acquisition of EncoreRx Automation.
- Represented TJM Labs in its acquisition of Pharmesol.
- Represented AbsCi in its acquisition of Totient.
- Represented Advanced Biologics in its merger with Isto Biologics.
- Represented Mablink Bioscience in its sale to Eli Lilly and Company.
Professional Highlights
Speaking Engagements
- “From Breakthrough to Bedside: Aligning Regulatory Strategy, Clinical Evidence and Commercialization in Diagnostics,” Webinar, June 17, 2026. Speaker.
- “Business Negotiations Skills,” University of California Los Angeles, May 20, 2026. Speaker.
- “Startup Groundwork: Establishing a Solid Legal Foundation in the U.S. Health Care Market,” Pillsbury Silicon Valley Office, May 14, 2026. Speaker.
View More
- “MedInvest Biotech & Pharma Investor Conference,” Pillsbury New York Office, April 1, 2026. Speaker.
- “Deep Tech Connections Alignment Summit,” Santa Clara, Healthtech Room, April 30, 2026. Speaker.
- “Capital 4 Growth Dinner DxPx Conference EU 2026,” Munich, Feb. 5, 2026. Speaker.
Education
-
J.D., University of Chicago Law School, 2010
B.S., University of Oregon, 2007
with honors
Admissions
-
California